NASDAQ · CELZHealthcareBiotechnology

Creative Medical Technology Holdings financials

$0.9652−4.44%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$6.0K$11.0K$9.0K$88.6K$87.8K
Gross profit$3.8K$6.6K$5.4K$60.1K$39.8K
Gross margin63.4%60.0%60.0%67.8%45.4%
Operating income-$6.1M-$5.7M-$5.6M-$10.2M-$3.1M
Net income-$6.0M-$5.5M-$5.3M-$10.1M$19.2M
Net margin−99916.8%−49940.7%−58739.7%−11449.3%21892.8%
Diluted EPS$-2.52$-3.71$-3.76$-9.28$56.10
EBITDA-$6.0M-$5.6M-$5.5M-$10.2M-$3.0M
Operating cash flow-$5.9M-$5.3M-$8.0M-$7.8M-$2.2M
Free cash flow-$5.9M-$5.3M-$8.0M-$7.8M—
Diluted shares2.4M1.5M1.4M1.1M0.3M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$7.2M$5.9M$3.5M$8.3M$10.7M
Short-term investments$0.00$0.00$6.5M$10.1M$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Total assets$7.8M$6.7M$10.7M$19.2M$11.3M
Total liabilities$284.9K$327.6K$371.4K$3.3M$1.1M
Shareholders' equity$7.5M$6.3M$10.3M$15.9M$10.2M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology